Biblio
18F-FDG PET/CT for Detection of Leukemic Transformation in Myelofibrosis. Clin Nucl Med. 2015.
. 5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity. Mediators Inflamm. 2014;2014:418292.
. Allogeneic hematopoetic stem cell transplant for patients with refractory T-Cell lymphomas. Eur J Haematol. 2023.
. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2022.
Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2024.
Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2023.
Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT. Bone Marrow Transplant. 2023.
Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study. Haematologica. 2023.
Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transplant. 2019.
Allogeneic stem cell transplantation for myelofibrosis patients aged ≥ 65 years. Eur J Haematol. 2019.
. Allogeneic Stem Cell Transplantation for patients with lower risk MDS. Biol Blood Marrow Transplant. 2020.
. Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL-mutation. Eur J Haematol. 2019.
Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2019.
An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Transplant Cell Ther. 2022.
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med. 2016;374(1):43-53.
Assessment of Quality of Life Following Allogeneic Stem Cell Transplant for Myelofibrosis. Biol Blood Marrow Transplant. 2019.
Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT. Bone Marrow Transplant. 2021.
ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF. Leukemia. 2018.
. B cell maturation antigen-specific CAR T cells for relapsed or refractory multiple myeloma: a meta-analysis. Eur J Haematol. 2019.
. Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplant. 2023.
Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.